TrialESMO open2021

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.

P Pautier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.